Viking Therapeutics begins Phase 1 trial of obesity candidate VK3019
Shares rose on the trial start, which adds a second asset to the company's obesity programme alongside renewed takeover speculation.
PR
By Priya Raman · Science Reporter
Jun 24 03:00 ETSource: kavout.com
The wire
- 01Viking Therapeutics started a Phase 1 study of VK3019, broadening its obesity pipeline, and the stock moved higher on the news.
- 02Readers tracking incretin competitors get another early-stage entrant, though Phase 1 work says nothing yet about efficacy or tolerability.
- 03No dosing, enrolment or timeline details were disclosed in the report, and the merger talk is speculation rather than a company statement.
From the source
Read at kavout.comViking Therapeutics: VK3019's Phase 1 Launch Ignites M&A Speculation and Diversifies Obesity Pipeline
Viking Therapeutics' VK3019 Phase 1 launch boosted its obesity pipeline. The news caused its stock to surge, sparking M&A speculation. Investors are optimistic about the company's diversified approach.
